Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APLS Apellis Pharmaceuticals Inc.

Post-Mkt 12-22 16:14:29 EST

25.40

+0.75

+3.04%

盘后25.40

+0.000.00%

16:10 EST

High26.12	Low24.40	Vol3.56M
Open24.67	D1 Closing24.65	Amplitude6.98%
Mkt Cap3.21B	Tradable Cap1.98B	Total Shares126.53M
T/O90.68M	T/O Rate4.56%	Tradable Shares78.12M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"APLS","market":"US","secType":"STK","nameCN":"Apellis Pharmaceuticals Inc.","latestPrice":25.4,"timestamp":1766437200000,"preClose":24.65,"halted":0,"volume":3561515,"hourTrading":{"tag":"盘后","latestPrice":25.4,"preClose":25.4,"latestTime":"16:10 EST","volume":16087,"amount":408609.8,"timestamp":1766437846449},"delay":0,"floatShares":78119932,"shares":126525218,"eps":0.35814,"marketStatus":"Post-Mkt","change":0.75,"latestTime":"12-22 16:14:29 EST","open":24.67,"high":26.12,"low":24.4,"amount":90677888.55023,"amplitude":0.069777,"askPrice":25.9,"askSize":77,"bidPrice":24.91,"bidSize":80,"shortable":3,"etf":0,"ttmEps":0.35814,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766451600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1510203600000,"exchange":"NASDAQ","adjPreClose":24.65,"preHourTrading":{"tag":"盘前","latestPrice":24.8,"preClose":24.65,"latestTime":"09:20 EST","volume":72,"amount":1779.6799440000002,"timestamp":1766413245246},"postHourTrading":{"tag":"盘后","latestPrice":25.4,"preClose":25.4,"latestTime":"16:10 EST","volume":16087,"amount":408609.8,"timestamp":1766437846449},"volumeRatio":1.139399,"impliedVol":0.6374,"impliedVolPercentile":0.608},"requestUrl":"/m/hq/s/APLS","defaultTab":"news","newsList":[{"id":"2592416974","title":"Apellis Pharmaceuticals Inc : Stifel Cuts Target Price to $48 From $55","url":"https://stock-news.laohu8.com/highlight/detail?id=2592416974","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592416974?lang=en_us&edition=fundamental","pubTime":"2025-12-19 20:07","pubTimestamp":1766146054,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nFWN3XP0SI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1093756168.USD","BK4588","LU1093756325.SGD","BK4505","APLS","BK4139","BK4585"],"gpt_icon":0},{"id":"2592156269","title":"U.S. RESEARCH ROUNDUP-Carmax, Cintas, Nike","url":"https://stock-news.laohu8.com/highlight/detail?id=2592156269","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592156269?lang=en_us&edition=fundamental","pubTime":"2025-12-19 15:33","pubTimestamp":1766129636,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Carmax, Cintas, NikeDec 19 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Carmax, Cintas and Nike","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nL4N3XP0JI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRO","CRCL","LU0300736492.USD","BANC","APLS","AZTA","BWIN","BK4022","CAT","CE","AX","CHRW","CL","LU0823434740.USD","BKU","AVAV","AA","AJG","COST","ALB","BRBR","LU1868836914.USD","ARCB","ARDT","CELH","BA","COGT","IE00BKPKM429.USD","IE00B42XCP33.USD","LU1868837136.USD","LU1032955483.USD","CATY","CFG","CLX","AGCO","CRWV","KO","BCSF","LU2097829019.USD","AIZ","CMA","ATI","APD","CCC","COLB","CTAS","BOKF","LU0175139822.USD","KMX","MO"],"gpt_icon":1},{"id":"2592907181","title":"Apellis Pharmaceuticals General Counsel David O. Watson Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592907181","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592907181?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:07","pubTimestamp":1766092032,"startTime":"0","endTime":"0","summary":"David O. Watson, General Counsel of Apellis Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL697GCd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Apellis Pharmaceuticals General Counsel David O. Watson Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","BK4585","BK4139","BK4505","BK4588","LU1093756168.USD","APLS"],"gpt_icon":0},{"id":"2591548658","title":"Is Apellis Pharmaceuticals Attractive After Recent 26% Surge Despite Mixed Valuation Signals?","url":"https://stock-news.laohu8.com/highlight/detail?id=2591548658","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591548658?lang=en_us&edition=fundamental","pubTime":"2025-12-13 23:41","pubTimestamp":1765640497,"startTime":"0","endTime":"0","summary":"Wondering if Apellis Pharmaceuticals is finally offering real value at today’s price, or if it is just another biotech value trap in disguise, you are not alone.\nThe stock has jumped 6.8% over the last week and 26.0% over the past month, even though it is still down 23.9% year to date and 24.0% over the past year. This tells you sentiment has started to shift, but long-term holders may still be underwater.\nThat recent surge has been driven largely by improving confidence in the commercial...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/is-apellis-pharmaceuticals-attractive-after-recent-26-surge","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/is-apellis-pharmaceuticals-attractive-after-recent-26-surge","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1093756325.SGD","APLS","DCF","BK4139","LU1093756168.USD","BK4588","BK4585","BK4505"],"gpt_icon":0},{"id":"2590176509","title":"Sobi Wins Positive CHMP Opinion for Aspaveli in Rare Kidney Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2590176509","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590176509?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:05","pubTimestamp":1765544728,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Swedish Orphan Biovitrum AB published the original content used to generate this news brief on December 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL3xt4vg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1093756168.USD","LU1093756325.SGD","APLS","BK4585","BK4588","BK4505"],"gpt_icon":0},{"id":"2588027421","title":"Apellis Reports Positive Phase 3 Results for Its Kidney Disease Treatment Empaveli","url":"https://stock-news.laohu8.com/highlight/detail?id=2588027421","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588027421?lang=en_us&edition=fundamental","pubTime":"2025-12-04 06:42","pubTimestamp":1764801725,"startTime":"0","endTime":"0","summary":"Apellis  said Wednesday the New England Journal of Medicine published positive Phase 3 results for Empaveli, its treatment for rare kidney diseases.The study showed a 68% reduction in proteinuria, the presence of an abnormal amount of protein in the urine, at Week 26, along with stabilization of kidney function and reduced C3 staining, the company said.Results were consistent across adults and adolescents, including patients whose disease returned after a transplant. Empaveli is already Food and Drug Administration-approved for patients 12 and older.Shares of the company were up over 1% in after-hours trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756168.USD","BK4588","BK4505","BK4139","APLS","BK4585","LU1093756325.SGD"],"gpt_icon":0},{"id":"2588221170","title":"Apellis Wins FDA Approval for EMPAVELI in Rare Kidney Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2588221170","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588221170?lang=en_us&edition=fundamental","pubTime":"2025-12-04 06:05","pubTimestamp":1764799515,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL2Ghlzp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU1093756168.USD","LU2095319765.USD","BK4505","IE00BGHQF748.EUR","BK4139","APLS","BK4585","IE00B64PRP62.GBP","LU0314104364.USD","LU1093756325.SGD","BK4588","LU2210149790.SGD","LU2210150020.SGD","NDAQ","BK4112"],"gpt_icon":0},{"id":"2588062159","title":"Assessing Apellis Pharmaceuticals (APLS) Valuation Following Five-Year SYFOVRE Efficacy Data in Geographic Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588062159","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588062159?lang=en_us&edition=fundamental","pubTime":"2025-12-03 06:32","pubTimestamp":1764714747,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals (APLS) has released new results from its Phase 3 GALE extension study. The findings highlight that SYFOVRE slowed disease progression for patients with geographic atrophy linked to age-related macular degeneration over five years.\nSee our latest analysis for Apellis Pharmaceuticals.\nApellis Pharmaceuticals' latest data on SYFOVRE comes as the company recently presented at a major healthcare conference, which is helping keep attention on its pipeline. Despite this...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/assessing-apellis-pharmaceuticals-apls-valuation-following-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/assessing-apellis-pharmaceuticals-apls-valuation-following-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4505","BK4139","LU1093756325.SGD","BK4585","BK4588","APLS","LU1093756168.USD"],"gpt_icon":0},{"id":"2586853420","title":"Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2586853420","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586853420?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:00","pubTimestamp":1764072017,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals Inc. will participate in webcast fireside chats at two upcoming investor conferences. The company will join Citi's 2025 Global Healthcare Conference on Tuesday, December 2, 2025, at 2:30 p.m. ET, and the Evercore 8th Annual Healthcare Conference on Wednesday, December 3, 2025, at 2:10 p.m. ET. Live webcasts will be available on the Apellis website, with replays accessible for approximately 30 days following the events.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on November 25, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL7R8NxB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","APLS","LU0314104364.USD","LU0477156953.USD","LU1366192091.USD","BK4505","BK4588","BK4112","LU2125154935.USD","LU1791807156.HKD","LU0128525689.USD","EVR","LU0052756011.USD","LU1668664300.SGD","NDAQ","LU0130517989.USD","BK4207","BK4585","BK4127","LU2417539215.USD","LU2456880835.USD","IE00BKPKM429.USD","LU2360032135.SGD","BK4534","IE00B3QW5Z07.USD","IE00BSNM7G36.USD","LU1244550221.USD","LU0320765646.SGD","LU1201861249.SGD","LU2210150020.SGD","LU0310800965.SGD","LU2210149790.SGD","LU2462157665.USD","IE00BGHQF748.EUR","BK4139","LU0162691827.USD","LU0170899867.USD","LU2125154778.USD","LU0130102774.USD","LU1244550577.SGD","LU1093756168.USD","LU0648001328.SGD","LU1162221912.USD","LU1244550494.USD","LU1267930227.SGD","BK4566","LU0098860793.USD","LU0072461881.USD","LU0980610538.SGD","LU0106831901.USD"],"gpt_icon":0},{"id":"2584956278","title":"Apellis Pharmaceuticals General Counsel David Watson Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584956278","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584956278?lang=en_us&edition=fundamental","pubTime":"2025-11-18 23:06","pubTimestamp":1763478362,"startTime":"0","endTime":"0","summary":"David O. Watson, General Counsel of Apellis Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDLb1rZFz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Apellis Pharmaceuticals General Counsel David Watson Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1093756168.USD","BK4585","APLS","BK4505","BK4139","LU1093756325.SGD"],"gpt_icon":0},{"id":"2583680024","title":"H.C. Wainwright Sticks to Its Buy Rating for Apellis Pharmaceuticals (APLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583680024","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583680024?lang=en_us&edition=fundamental","pubTime":"2025-11-15 07:38","pubTimestamp":1763163525,"startTime":"0","endTime":"0","summary":"In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Apellis Pharmaceuticals, with a price target of $45.00. Ac...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-apellis-pharmaceuticals-apls-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-apellis-pharmaceuticals-apls-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APLS"],"gpt_icon":0},{"id":"2583402301","title":"This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power","url":"https://stock-news.laohu8.com/highlight/detail?id=2583402301","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583402301?lang=en_us&edition=fundamental","pubTime":"2025-11-13 02:36","pubTimestamp":1762972560,"startTime":"0","endTime":"0","summary":"Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/12/Medical-Research.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/12/Medical-Research.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48814129/this-undervalued-biotech-might-have-just-proven-its-star-drugs-staying-power","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48814129/this-undervalued-biotech-might-have-just-proven-its-star-drugs-staying-power","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4614","LU0823434583.USD","PM","IE0004445239.USD","LU1064131342.USD","LU1121112475.USD","LU1951200564.SGD","BK4141","LU0823421333.USD","LU1066051811.HKD","LU2250418816.HKD","LU0056508442.USD","LU1066051498.USD","LU0109392836.USD","BK4084","LU0198837287.USD","LU0274383776.USD","LU2458330243.SGD","BK4529","LU0979878070.USD","LU1923623000.USD","BK4505","IE00BMPRXR70.SGD","LU2264538146.SGD","LU1228905540.USD","APLS","BK4585","LU0390134368.USD","LU0265550946.USD","BK4234","LU1861558580.USD","BK4543","SG9999011175.SGD","BK4566","LU0994945656.USD","LU1242518931.SGD","LU1803068979.SGD","LU2089985449.USD","BK4512","LU1043141396.HKD","LU1852331112.SGD","SG9999001440.SGD","BK4605","PW","LU1043141123.HKD","LU0690374615.EUR","LU1989764664.SGD","BK4534","LU2458330169.SGD"],"gpt_icon":1},{"id":"2582375875","title":"Apellis Pharmaceuticals: Safety Profile of Syfovre Through Five Years Remained Consistent With Previously Reported Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375875","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375875?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:05","pubTimestamp":1762949143,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO0IP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","BK4588","APLS","LU1093756168.USD","BK4585","LU1093756325.SGD"],"gpt_icon":0},{"id":"2582373035","title":"Apellis Announces 5-Year Gale Data Showing Syfovre® (Pegcetacoplan Injection) Delayed Progression of Geographic Atrophy by ~1.5 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373035","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373035?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:05","pubTimestamp":1762949143,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO0IP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU1093756168.USD","BK4588","BK4585","BK4505","APLS","LU1093756325.SGD"],"gpt_icon":0},{"id":"2582373153","title":"Apellis Reports SYFOVRE Delays Geographic Atrophy Progression by 1.5 Years in Five-Year Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2582373153","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582373153?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:00","pubTimestamp":1762948849,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals Inc. has announced data from a post hoc analysis of the GALE extension study, evaluating the long-term effects of SYFOVRE  in patients with geographic atrophy  secondary to age-related macular degeneration. The study showed that five years of continuous treatment with SYFOVRE delayed GA lesion growth by approximately 1.5 years in patients with nonsubfoveal GA compared to sham/projected sham. The safety profile remained consistent with previous data. The company stated that detailed results will be presented at a future medical meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on November 12, 2025","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL2qYBss:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","NDAQ","LU1093756325.SGD","BK4505","BK4139","BK4588","LU1093756168.USD","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4585","IE00BKPKM429.USD","APLS"],"gpt_icon":0},{"id":"2581096591","title":"Apellis Pharmaceuticals Initiated at Peer Perform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2581096591","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581096591?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:36","pubTimestamp":1762436160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/APLS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 06, 2025 08:36 ET (13:36 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","BK4588","BK4585","LU1093756168.USD","BK4139","APLS","BK4505"],"gpt_icon":0},{"id":"2581067490","title":"Wolfe Research Initiates Coverage on Apellis Pharmaceuticals With Peer Perform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581067490","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581067490?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:21","pubTimestamp":1762431687,"startTime":"0","endTime":"0","summary":"Wolfe Research Initiates Coverage on Apellis Pharmaceuticals With Peer Perform Rating","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","APLS","BK4505","LU1093756168.USD","BK4585","LU1093756325.SGD","BK4588"],"gpt_icon":0},{"id":"2581724686","title":"J.P. Morgan Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581724686","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581724686?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:18","pubTimestamp":1762345099,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Anupam Rama maintained a Buy rating on Apellis Pharmaceuticals today and set a price target of $36.00. The company’s shares clo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-reaffirms-their-buy-rating-on-apellis-pharmaceuticals-apls-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-reaffirms-their-buy-rating-on-apellis-pharmaceuticals-apls-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APLS"],"gpt_icon":0},{"id":"1155080466","title":"Stock Track | Apellis Pharmaceuticals Plummets 5.05% as Mizuho Slashes Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1155080466","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155080466?lang=en_us&edition=fundamental","pubTime":"2025-11-04 01:56","pubTimestamp":1762192591,"startTime":"0","endTime":"0","summary":"Shares of Apellis Pharmaceuticals Inc. (APLS) took a sharp dive in Monday's intraday trading, plummeting 5.05% following a significant price target cut by a major financial firm. The biotechnology...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["APLS"],"gpt_icon":0},{"id":"1142019377","title":"Stock Track | Apellis Pharmaceuticals Plunges 5% as Mizuho Slashes Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1142019377","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142019377?lang=en_us&edition=fundamental","pubTime":"2025-11-04 01:56","pubTimestamp":1762192586,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals Inc. (APLS) saw its stock price plummet by 5.05% during Monday's intraday trading session, with shares falling to new lows following a significant price target cut by a major...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["APLS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apellis.com","stockEarnings":[{"period":"1week","weight":-0.023},{"period":"1month","weight":0.2674},{"period":"3month","weight":0.0713},{"period":"6month","weight":0.3934},{"period":"1year","weight":-0.2562},{"period":"ytd","weight":-0.2275}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.0274},{"month":2,"riseRate":0.625,"avgChangeRate":0.032574},{"month":3,"riseRate":0.5,"avgChangeRate":0.022263},{"month":4,"riseRate":0.625,"avgChangeRate":0.039768},{"month":5,"riseRate":0.375,"avgChangeRate":-0.036849},{"month":6,"riseRate":0.75,"avgChangeRate":0.072936},{"month":7,"riseRate":0.625,"avgChangeRate":-0.050758},{"month":8,"riseRate":0.875,"avgChangeRate":0.155594},{"month":9,"riseRate":0.125,"avgChangeRate":-0.147812},{"month":10,"riseRate":0.375,"avgChangeRate":0.006953},{"month":11,"riseRate":0.625,"avgChangeRate":0.128375},{"month":12,"riseRate":0.777778,"avgChangeRate":0.12786}],"exchange":"NASDAQ","name":"Apellis Pharmaceuticals Inc.","nameEN":"Apellis Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Apellis Pharmaceuticals Inc.(APLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Apellis Pharmaceuticals Inc.,APLS,Apellis Pharmaceuticals Inc.股票,Apellis Pharmaceuticals Inc.股票老虎,Apellis Pharmaceuticals Inc.股票老虎国际,Apellis Pharmaceuticals Inc.行情,Apellis Pharmaceuticals Inc.股票行情,Apellis Pharmaceuticals Inc.股价,Apellis Pharmaceuticals Inc.股市,Apellis Pharmaceuticals Inc.股票价格,Apellis Pharmaceuticals Inc.股票交易,Apellis Pharmaceuticals Inc.股票购买,Apellis Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Apellis Pharmaceuticals Inc.(APLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}